hotspot -WSS

hotspot

author：entertainment 2025-10-01 00:59:25 - browse：16929

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Timeline: How the deadly wildfires took over Maui day by day

WSS

PBM reform efforts get punted in Congress

Illumina slashes 2023 revenue projections yet again

Novo Nordisk touts Wegovy study, but still struggling with supply

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

After Optum profits sink, UnitedHealth makes changes

hotspot

hotspot

hotspot

Jerome Adams on the need for new antivirals for Covid

Novo Nordisk touts Wegovy study, but still struggling with supply

Cancer drug shortages should be causing more outrage

YouTube cracks down on misinformation on cancer treatment

Medical records are filled with copy

Medicare inequities exacerbate Puerto Rico’s health disparities

23andMe had bad news about my health. I wish a person had delivered it

Indictment alleges Trump's ex

Supreme Court strikes down use of affirmative action

Schizophrenia gene found to be linked to cells' energy dysfunction

leisure time

A new nitrogen execution bill also undermines medical licensing

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Judge sides with young activists in first

Indictment alleges Trump's ex

Medicare inequities exacerbate Puerto Rico’s health disparities

explore

entertainment

entertainment

focus